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INJECTABLE
Dynamics of Injectable 
Contraceptive Use in India
Quality of care received and interim results 
three months after first injection
ENROLLMENT
KEY RECOMMENDATIONS
Disseminate messaging about potential side effects of the injectable, including amenorrhea or 
other changes to menstruation
The findings demonstrate a need to provide information about side effects to clients. In particular, providers 
and accredited social health activists (ASHA) should inform women that amenorrhea is a potential side effect 
and alleviate any concerns related to fertility. Furthermore, social behavioral change programs may consider 
including specific messaging on injectables and amenorrhea in addition to other common side effects.
Institutionalize quality of care in pre-service trainings for all family planning providers and 
frontline health workers
To improve quality of care during family planning visits for all contraceptive methods, providers and front-
line health workers should receive training focusing on all four domains of quality of care: 1) respectful 
care, 2) counseling to enable appropriate method selection, 3) counseling on effective use of method 
chosen, and 4) information on continuation of contraceptive use and care. Particularly for injectable users, 
many did not want any more children so there is an opportunity to counsel them on a range of methods 
that include long-acting and permanent methods.
Engage husbands of recent adopters of contraception
Most women who discontinued the injectable spoke to their husband about their desire to stop using the 
method. The advice given by most of these husbands was to stop using the method and only seven percent 
suggested switching to another modern method. As women are going to their husbands for support, there 
is an opportunity to improve continuation and switching to a modern method if husbands are equipped 
with relevant information.
Train frontline health workers to visit recent injectable adopters to answer and address 
concerns about injectable side effects, and counsel women on method switching
Frontline health workers can play a key role in promoting modern method switching among recent adopters 
of the injectable who are dissatisfied with the method. ASHAs should visit all women who are using the 
injectable to a) understand their concerns with the method, b) understand their fertility desires, and c) help 
them manage any side effects they might experience. They should also encourage those who want to stop 
the injectable but continue preventing pregnancy to switch to another suitable method.
1. To assess one-year modern spacing contraceptive 
discontinuation rates by modern spacing methods 
(postpartum IUD/interval IUD, injectables, OCPs) 
among a cohort of modern spacing contraceptive 
users.
2. To measure influencing facilitators for contracep-
tive continuation and discontinuation, including 
intensity of experienced side effects.
3. To measure the Method Information Index (MII) 
that measures client’s recall of counseling infor-
mation received.
4. To assess influ-
encing factors that 
lead to contracep-
tive switching or 
non-switching.




and switching, and 
their practices with 
clients who want 




Injectable contraceptive methods (DMPA and 
Net-En) have been approved for private sector provi-
sion in India since 1993 (FHI, 2010). However, a 
very small proportion of women use injectables: 
injectable use among currently married women has 
remained low over time at less than 0.05 percent in 
1992-93, 0.1 percent in 2005-06, and 0.2 percent in 
2015-16 (IIPS, 1995; IIPS and Macro International, 
2007; IIPS and ICF, 2017). In 2016, injectables were 
included in India’s National Family Planning Program 
with the introduction of Antara, a brand of DMPA, 
a three-month progestin-only injectable contracep-
tive (MOHFW, 2016b). Under Mission Parivar Vikas 
(Family Development Mission), the Antara program 
rolled out injectables to the sub-center level in prior-
ity districts (identified as having a total fertility rate of 
at least three children per woman), and at medical 
colleges and district hospitals in all states (MOHFW, 
2016a, MOHFW, 2017a, MOHFW, 2017b). Through 
the introduction of Antara, the Indian Government is 
increasing its basket of method choice in an effort to 
achieve its FP2020 goals. 
Given that roll out of the injectable is ongoing 
throughout India, it is important to understand the 
experiences of current injectable users. This brief 
describes the characteristics of a sample of inject-
able users in India, reported quality of care they 
received at the time of first injection (this study did 
not observe providers during counseling interac-
tions), contact with frontline health workers, and 
continuation three months after initial injection. 
Briefs focusing on oral contraceptive pills and IUD/
PPIUD are available as well (see Box 1) but are not 
the focus of this brief.
METHODS
Box 1 presents the methodology of the longitudinal 
study of reversible contraceptive users in India. Of 
2,699 users enrolled into the study, 581 were inject-
able users and are the focus of this brief. 
Map 1
Study Implementation Sites
INDIA CONTRACEPTIVE USE DYNAMICS LONGITUDINAL STUDY METHODS
Through the Evidence Project, Population Council 
researchers are conducting a longitudinal study 
of 2,699 married women aged 15-49 who began 
using IUD/PPIUD, injectable, or oral contraceptive 
pill (OCP). These reversible contraceptive users are 
first being interviewed within one month of starting 
the method (known as the enrollment survey) and at 
3-, 6- and 12-months follow-up. Respondents from 
Haryana and Odisha states in India were enrolled into 
the study from December 2016 to October 2017 (see 
Map 1). In Haryana, all respondents were recruited 
through accredited social health activists (ASHAs) at 
the community level. In Odisha, PPIUD users were 
recruited at government health facilities, interval 
IUD and OCP users were recruited primarily through 
ASHAs, and injectable users were recruited primarily 
at non-governmental organization (NGO) facilities.
The purpose of this research study is to provide 
evidence that can be used to strengthen the family 
planning program and meet the needs of reversible 
contraceptive users who want to prevent pregnancy 
in India. With support from USAID/India, Population 
Council researchers are exploring contraceptive use 
dynamics of married women by conducting a cohort 
study with the following research objectives:




The median age of injectable users enrolled in this 
study was 28 years, with a range from 18 to 46 years. 
Nearly half of respondents had attended secondary 
school or higher (46%), while 30 percent had never 
attended school (Figure 1). Two-thirds of respondents 
were Hindu (67%) and one-third were Muslim (32%). 
Most respondents were homemakers (94%), two 
percent were teachers/clerks and two percent were 
factory/production workers.  While all respondents 
were married, about nine percent were not living with 
their husband at the time of the enrollment survey. 
Fifty-four percent owned mobile phones. 
Two-thirds of injectable users in this sample (69%) 
had used contraception in the past. Among those 
who reported previously using a method (n=424), 
the most recently used methods were the OCP 
(32%), condoms (27%), abstinence (10%), with-
drawal (10%), injectables (10%), IUD (5%), rhythm 
method (4%), female condoms (1%), lactational 
amenorrhea method (1%), or the emergency contra-
ceptive pill (1%). The median age at first contracep-
tive use was 24 years. (Data not shown).
Nearly all injectable users had at least one living child 
(over 99%). One-quarter had one child (25%), 39 
percent had two children, and 36 percent had three 
or more. More than three-quarters of respondents did 
not want any children in the future (Figure 2, 78%). 
Twelve percent wanted to wait more than two years 
before having a child, six percent wanted to wait one 
to two years, one percent wanted a child within the 
next year, and four percent were undecided. 
QUALITY OF CARE RECEIVED
Forty-six percent of respondents received their first 
administration of the injectable at an NGO clinic. 
Thirty-seven percent received their first injection 
from a government health facility, 11 percent from a 
medical store, 4 percent from a private facility, and 2 
percent from a frontline health worker. Figure 3 pres-
ents 22 items measuring quality of care received 
during this visit. These measures of quality are 
broken down into four domains of process quality 
(Jain, Townsend & Ramarao 2018): 1) respectful 
care, 2) method selection, 3) effective use of the 
selected method, and 4) continuity of contraceptive 
use and care (see Box 2).
Respectful care
Injectable users reported high levels of respectful 
care at initial visit. Nearly all women reported a) 
being treated well or very well by the provider (99%), 
b) that their questions were answered to their satis-
faction (98%), and c) that they were allowed to ask 
questions (92%). Most felt that others couldn’t hear 
(87%) or see (82%) them during their visit, and that 
their information would be kept confidential (86%).  
Method selection
The majority of injectable users reported that their 
provider asked their preferred family planning 
method (86%), their desire for another child (85%), 
Figure 1
Background characteristics of injectable users (n=581)
Figure 2
Percent distribution of injectable users by fertility 
preferences at enrollment (n=581)
4and their preferred timing of next child (80%). 
Slightly fewer were asked about their previous family 
planning experience (72%), and two-thirds were 
told about other methods (66%). Only 40 percent 
received information about methods that protect 
against STIs and 38 percent received information 
without any method being strongly encouraged.  
Effective use of selected method
Most respondents were told how to use the method 
(92%) while only two-thirds were told how the 
method works (67%). Less than half of respondents 
were told about both the method’s side effects as 
well as what to do if they experienced side effects 
(45%).  Of the potential side effects of the injectable, 
the most common mentioned by providers were 
irregular menstruation (39%), spotting (17%), weight 
gain (14%), backache (11%), and nausea (11%). 
Just 43 percent were told of the warning signs of 
the method.  
Figure 3
Aspects of process quality during initial visit reported by injectable users (n=581)
What is quality of care?
Measures of quality are broken down into four 
domains of process quality (Jain et al., 2018):
1. Respectful care: Concerns interpersonal 
interactions between the provider and client and 
assesses aspects of privacy and confidentiality.
2. Method selection: Questions focus on information 
that a provider should seek to enable appropriate 
method selection at the decision-making point.
3. Effective use of the selected method: Information 
given to the respondent about the method 
selected.
4. Continuity of contraceptive use and care: Includes 
follow-up appointments and the ability to change 
methods.
Box 2
5Continuity of contraceptive use and care
Four in five injectable users (81%) were told when 
to return to the facility for their next injection, and 
three quarters were given an appointment card for 
this visit (75%). Sixty-four percent were told about 
the possibility of switching to other methods if the 
injectable was not suitable, while only 45 percent 
were told of other sources of injectable supply. 
CONTRACEPTIVE METHOD DECISION 
MAKING
All respondents were asked who made the final 
decision about the method they received at enroll-
ment after discussions with the provider (Figure 4). 
Among injectable users, 96 percent reported that 
they were involved in the final decision: 35 percent 
made the final decision by themselves, 53 percent 
made the final decision together with their husband, 
and eight percent made the final decision together 
with their health provider. Four percent reported that 
their husband, the provider, or someone else made 
the final decision. Ninety-eight percent of respon-
dents received the method that they wanted (data 
not shown). Reasons why women did not get their 
preferred method was not collected in this study. 
CONTACT WITH FRONTLINE HEALTH 
WORKERS
At enrollment, injectable users were asked about 
their contact with frontline health workers. Less than 
half had ever received information from a frontline 
health worker (45%). Regarding information about 
the injectable, 43 percent had received information 
about the injectable from an ASHA, one percent had 
received this information from an auxiliary nurse 
midwife (ANM), and 0.3 percent had received this 
information from an Anganwadi worker (AWW). In the 
three months preceding the survey, 55 percent did 
not meet with a frontline health worker, 9 percent 
met with a frontline health worker once, 28 percent 
met two to five times, and 8 percent met more than 
five times. (Data not shown).
Figure 5 presents the topics discussed with front-
line health workers in the three months preceding 
the survey. The most commonly discussed topic was 
available contraceptive methods (22%), followed by 
long acting methods (15%), fertility intentions (14%), 
side-effects of methods (10%), how to deal with side 
effects (7%), and return to fertility (3%). 
CONTRACEPTIVE USE AT THREE MONTHS 
FOLLOWING INITIAL INJECTION
Seventy-eight percent of injectable users completed 
the three-month follow-up survey (n=455). Three 
months after their first injection, 76 percent were 
still using the injectable method. The 24 percent 
that discontinued the injectable includes 8 percent 
who switched to another modern method, 4 percent 
who switched to a traditional method, and 11 
percent who stopped contraceptive use altogether. 
The modern methods switched to after the inject-
able were the OCP (5% of all injectable users inter-
viewed at three-month), condom (2%), IUD (1%), and 
male and female sterilization (0.2% each). Among 
those who discontinued the injectable and did not 
switch to another method (n=51), most still had a 
need for family planning as 69 percent did not want 
any children in the future and 10 percent wanted to 
wait more than two years before having a child. 
Figure 4
Percent distribution of injectable users by who made the 
final decision about contraceptive method (n=581)
Figure 5
Topics discussed with frontline health workers in the three 
months preceding the survey reported by injectable users 
(n=581)
6Reasons for injectable discontinuation
Respondents who discontinued the injectable (both 
those who discontinued contraception altogether 
and those who switched to another method, n=104) 
provided one or more reasons why they discontin-
ued the method (Figure 6). Common reasons named 
were having not menstruated since starting the 
method (57%), and side effects and health concerns 
(33%). Other reasons mentioned were husband’s 
opposition (16%), injectable use interfered with the 
body’s normal processes (9%), husband not living 
at home (8%), lack of access to the method/too far 
(7%), mother-in-law’s opposition (5%), not having 
sex (5%), and method failure/pregnancy (4%). Only 
3 percent discontinued the injectable because they 
wanted to become pregnant. 
Discussions about discontinuation
Among respondents who had stopped using the 
injectable by three months (including those who 
switched and those who discontinued contracep-
tion altogether, n=104), fifty-two percent spoke to 
their husband about their desire to stop using the 
method (Figure 7). Twenty-seven percent spoke to 
an ASHA, 13 percent to a provider, seven percent to 
their mother-in-law, two percent to a neighbor, and 
one percent to a sister-in-law. Thirty-five percent of 
women spoke to no one about their desire to stop 
using the injectable. Respondents were also asked if 
they spoke to the same provider who gave them the 
injectable about stopping the method: 38 percent 
spoke to the same provider and 41 percent returned 
to the same facility (data not shown). 
Among respondents who spoke to an ASHA about 
their desire to stop the method (n=28), 13 women 
reported that the ASHA asked them to stop using the 
method, seven reported that the ASHA gave them 
medicine for side effects, and four said the ASHA 
accompanied them to a health center. Three said the 
ASHA counseled them about other methods and one 
said the ASHA told her to switch to a different method 
(data not shown). Among those who spoke to their 
husband (n=54), 42 reported that their husband 
asked them to stop using the injectable. Six respon-
dents said their husband told them to see a doctor/
ASHA, four said their husband asked them to switch 
to another method, one said her husband asked her 
to continue the injectable and one said her husband 
suggested getting medication (data not shown). 
Figure 8 presents the proportion of injectable discon-
tinuers who switched to another modern method by 
whom they spoke to about their desire to discon-
tinue. Those who spoke to an ASHA only were most 
likely to switch to another modern method (57%). 
Among those who spoke to both an ASHA and their 
husband, 36 percent switched to another modern 
method, while those who spoke to their husband 
only and those who spoke to neither their husband 
nor an ASHA were least likely to switch to another 
modern method (28 and 25 percent, respectively). 
Figure 7
Individuals with whom injectable discontinuers 
discussed their desire to discontinue the method 
(n=104)
Figure 8
Percent of injectable discontinuers who switched to a 
modern method, by whom they spoke to
Figure 6
Reasons for discontinuation reported by injectable 
discontinuers at three month follow-up (n=104)
7DISCUSSION
Understanding the experiences of the small but 
growing population of women choosing the inject-
able is important as the Government of India contin-
ues to rollout injectable contraceptive methods in 
the public sector. In this study, most injectable users 
were age 20-29 years, educated, and did not want 
any more children. Most were involved in the final 
decision about which contraceptive method to use 
after discussions with their provider. Less than half 
had spoken with a frontline health worker at least 
once in the three months preceding the survey. 
Injectable users’ reports demonstrate mixed results 
of their interactions with providers at initial visit. 
Some reported aspects of quality were high, such as 
items under the respectful care domain. There is an 
opportunity for improvement in other domains, such 
as providing important method-related information 
and alternative method choices in case the inject-
able is not suitable. Many women discontinued the 
injectable method because they had not menstru-
ated since starting the method. Providers should 
include information on amenorrhea in routine inject-
able counseling so potential users know to expect 
this as a potential result of use. 
Injectable users’ responses about their initial visit 
may have recall bias, but this is likely to be minimal 
as they were interviewed within one month of the 
visit in which they initiated the method. Additionally, 
45 percent of injectable users had received infor-
mation from a frontline worker about contraceptive 
methods in the three months preceding the enroll-
ment survey, but responses about quality of care at 
initiation of injectable use may not have included 
this prior counseling. 
Speaking to an ASHA only about the desire to 
discontinue the injectable appears to have a posi-
tive effect on women’s switching behavior as fifty-
seven percent of respondents who spoke to an 
ASHA only switched to another modern method. 
When women spoke to their husbands in addition 
to an ASHA, on the other hand, the positive effect of 
the ASHA on method switching was attenuated and 
the proportion switching to a modern method went 
down to thirty-six percent. It is therefore critical to 
both ensure ASHAs are visiting new users of inject-
ables and to equip husbands with information to 
encourage their wives to switch to another modern 
method of family planning in cases where the desire 
to prevent pregnancy remains.
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